The Type II anti-CD20 Antibody Obinutuzumab (GA101) is More Effective than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model

OBJECTIVE: Depleting pathogenic B cells could treat SLE. However, depleting B cells in the presence of an inflammatory setting such as lupus is difficult. We hypothesized that a Type II anti-CD20 mAb with a different mechanism–obinutuzumab (GA101)—could be more effective in depletion in lupus and th...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Arthritis Rheumatol
Autori principali: Marinov, Anthony D., Wang, Haowei, Bastacky, Sheldon I., van Puijenbroek, Erwin, Schindler, Thomas, Speziale, Dario, Perro, Mario, Klein, Christian, Nickerson, Kevin M., Shlomchik, Mark J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8084886/
https://ncbi.nlm.nih.gov/pubmed/33277983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.41608
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi